Biography
Biography: Jianhua Luo
Abstract
Accurate prediction of prostate cancer clinical courses remains elusive. In recent studies, we performed whole genome analysis on prostate cancers by combining Affymetrix SNP6.0 chip, whole genome sequencing and transcriptome sequencing. Our results showed that combination of genome copy number variance and novel fusion transcripts specific for cancer achieved high accuracy in predicting prostate cancer outcomes. The prediction model was further improved when these molecular criteria were combined with Nomogram or Gleason’s grading. Interestingly, some of these fusion genes are also present in a variety of human malignancies. One of these fusion genes, MAN2A1-FER appears a cancer driver since it induced cancer both in vivo and in vitro. Treatment of cancers with drugs specific for MAN2A1-FER signaling pathway produced dramatic improvement of metastasis and survival rate of animals xenografted with cancers positive for this fusion gene. Our analyses suggest that targeting therapy for fusion genes holds promise as an effective treatment for human cancers.
